| abstract |
Antibodies that bind CSF1 R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1 R are also provided. Polynucleotides encoding antibodies to CSF1 R are provided. Polynucleotides encoding antibody heavy chains and light chains are also provided. Methods of treatment using antibodies to CSF1 R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis. |